ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss - results from the ENGOT/GYN1/NCRI ATARI trial

5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the Phase III PAOLA-1/ENGOT-ov25 trial

Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Adjusted for Subsequent PARPi Use in Placebo Group: Results from an Ad Hoc Interim Analysis for the Phase 3 NORA Study

Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial

Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial

PRIMA/ENGOT-OV26/GOG-3012 study: long-term conditional PFS

Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial

Phase 1 analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer

Expression of CD47 a potent ‘don’t eat me’ signal’ in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study

Molecular Alterations Predictive of Outcome in Early Staged Cervical Cancer : a translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III